We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
- Authors
Bidard, François-Clément; Kiavue, Nicolas; Ychou, Marc; Cabel, Luc; Stern, Marc-Henri; Madic, Jordan; Saliou, Adrien; Rampanou, Aurore; Decraene, Charles; Bouché, Olivier; Rivoire, Michel; Ghiringhelli, François; Francois, Eric; Guimbaud, Rosine; Mineur, Laurent; Khemissa-Akouz, Faiza; Mazard, Thibault; Moussata, Driffa; Proudhon, Charlotte; Pierga, Jean-Yves
- Abstract
The management of patients with colorectal cancer (CRC) and potentially resectable liver metastases (LM) requires quick assessment of mutational status and of response to pre-operative systemic therapy. In a prospective phase II trial (NCT01442935), we investigated the clinical validity of circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) detection. CRC patients with potentially resectable LM were treated with first-line triplet or doublet chemotherapy combined with targeted therapy. CTC (Cellsearch®) and Kirsten RAt Sarcoma (KRAS) ctDNA (droplet digital polymerase chain reaction (PCR)) levels were assessed at inclusion, after 4 weeks of therapy and before LM surgery. 153 patients were enrolled. The proportion of patients with high CTC counts (≥3 CTC/7.5mL) decreased during therapy: 19% (25/132) at baseline, 3% (3/108) at week 4 and 0/57 before surgery. ctDNA detection sensitivity at baseline was 91% (N=42/46) and also decreased during treatment. Interestingly, persistently detectable KRAS ctDNA (p = 0.01) at 4 weeks was associated with a lower R0/R1 LM resection rate. Among patients who had a R0/R1 LM resection, those with detectable ctDNA levels before liver surgery had a shorter overall survival (p < 0.001). In CRC patients with limited metastatic spread, ctDNA could be used as liquid biopsy tool. Therefore, ctDNA detection could help to select patients eligible for LM resection.
- Subjects
CIRCULATING tumor DNA; COLORECTAL cancer; METASTASIS; POLYMERASE chain reaction; LIVER metastasis
- Publication
Cells (2073-4409), 2019, Vol 8, Issue 6, p516
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells8060516